Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

State-of-the-art preclinical testing of the OMEGATM left atrial appendage occluder

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Feasibility and safety of a fully percutaneous transcatheter aortic valve replacement program

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Implications of hydrodynamic testing to guide sizing of self-expanding transcatheter heart valves for valve-in-valve procedures

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Performance of the TRUE dilatation balloon valvuloplasty catheter beyond rated burst pressure: A bench study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intravascular iliac artery lithotripsy to enable transfemoral thoracic endovascular aortic repair

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Randomized blinded trial of automated REBOA during CPR in a porcine model of cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Feasibility and safety of a fully percutaneous transcatheter aortic valve replacement program

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2020 ESC Guidelines for the management of adult congenital heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: This study aimed to present a new approach of thorough preclinical testing of a novel left atrial appendage (LAA) occluder device.

BACKGROUND: The development of a safe and effective LAA occluder has been shown to be challenging.

METHODS: The novel OMEGATM LAA occluder (Eclipse Medical, Ireland) was tested in a porcine model and three-dimensional (3D) human LAA models - this as a prelude to its first-in-human use.

RESULTS: In a first series of in-vivo experiments, the OMEGATM LAA occluder was shown to have a satisfactory device biocompatibility in a porcine model. The design of the OMEGATM device was further refined and optimized following three more series of in-vivo experiments. The second generation OMEGATM device was designed with thinner wires, leading to a profile reduction. Based on in-vitro testing of different OMEGATM device sizes implanted at different depths in human three-dimensional (3D) LAA models, it could be determined that (1) the landing zone should be measured at a median depth of 12 mm from the LAA ostium; (2) the distal self-retaining inverted cup should have 10%-25% compression to minimize device embolization risk; and (3) the disc should be slightly inverted, i.e. pulled into the LAA, to promote complete LAA occlusion. The combined in-vivo and in-vitro testing resulted in an optimized pre-procedural planning of the first-in-human case treated with the OMEGATM device.

CONCLUSIONS: This series of carefully planned in-vivo and in-vitro experiments allowed demonstration of the safety and efficacy of the OMEGATM LAA occluder. This approach of thorough preclinical testing of medical devices may reduce the risk of complications in first-in-human cases and may become the standard approach for device development and preclinical testing in the future.

Original languageEnglish
JournalCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN1522-1946
DOIs
Publication statusE-pub ahead of print - 2021

ID: 62239925